Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients

doi:10.1001/jamainternmed.2023.5099

. 2023 Dec 1;183(12):1404-1406.

doi: 10.1001/jamainternmed.2023.5099.

Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients

Kin Wah Fung¹, Fitsum Baye¹, Seo H Baik^{1

2}, Clement J McDonald^{1

2}

Affiliations

¹ Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland.
² National Institutes of Health, Bethesda, Maryland.

PMID: 37870856
PMCID: PMC10594174
DOI: 10.1001/jamainternmed.2023.5099

Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients

Kin Wah Fung et al. JAMA Intern Med. 2023.

. 2023 Dec 1;183(12):1404-1406.

doi: 10.1001/jamainternmed.2023.5099.

Authors

Kin Wah Fung¹, Fitsum Baye¹, Seo H Baik^{1

2}, Clement J McDonald^{1

2}

Affiliations

¹ Lister Hill National Center for Biomedical Communications, National Library of Medicine, Bethesda, Maryland.
² National Institutes of Health, Bethesda, Maryland.

PMID: 37870856
PMCID: PMC10594174
DOI: 10.1001/jamainternmed.2023.5099

No abstract available

Plain language summary

This observational cohort study assesses the occurrence of post–COVID-19 condition symptoms in Medicare enrollees prescribed nirmatrelvir and molnupiravir.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Cited by

Long COVID Syndrome: A Narrative Review on Burden of Age and Vaccination.
Finamore P, Arena E, Lupoi D, Savito L, Di Nunzio F, Furbatto M, Dragonieri S, Antonelli Incalzi R, Scarlata S. Finamore P, et al. J Clin Med. 2024 Aug 13;13(16):4756. doi: 10.3390/jcm13164756. J Clin Med. 2024. PMID: 39200898 Free PMC article. Review.
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity.
Wimalawansa SJ. Wimalawansa SJ. Heliyon. 2024 Jul 17;10(15):e34691. doi: 10.1016/j.heliyon.2024.e34691. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39166024 Free PMC article. Review.
Long COVID science, research and policy.
Al-Aly Z, Davis H, McCorkell L, Soares L, Wulf-Hanson S, Iwasaki A, Topol EJ. Al-Aly Z, et al. Nat Med. 2024 Aug;30(8):2148-2164. doi: 10.1038/s41591-024-03173-6. Epub 2024 Aug 9. Nat Med. 2024. PMID: 39122965 Review.
Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients - A Large-Scale Observational Cohort Study from the RECOVER Initiative.
Wang F, Zang C, Li H, Khullar D, Zhang Y, Strobel S, Chen Y, Sala M, Patel P, Comellas A, Wylam A, Weiner M, Forrest C, Carton T, Kaushal R. Wang F, et al. Res Sq [Preprint]. 2024 Jun 20:rs.3.rs-4536807. doi: 10.21203/rs.3.rs-4536807/v1. Res Sq. 2024. PMID: 38947026 Free PMC article. Preprint.
Pathogenic mechanisms of cardiovascular damage in COVID-19.
Shao HH, Yin RX. Shao HH, et al. Mol Med. 2024 Jun 19;30(1):92. doi: 10.1186/s10020-024-00855-2. Mol Med. 2024. PMID: 38898389 Free PMC article. Review.

See all "Cited by" articles

References

1. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2 - DOI - PMC - PubMed
1. Hammond J, Leister-Tebbe H, Gardner A, et al. ; EPIC-HR Investigators . Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542 - DOI - PMC - PubMed
1. Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554-564. doi:10.1001/jamainternmed.2023.0743 - DOI - PMC - PubMed
1. Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381:e074572. doi:10.1136/bmj-2022-074572 - DOI - PMC - PubMed
1. Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US. PLoS Med. 2023;20(4):e1004194. doi:10.1371/journal.pmed.1004194 - DOI - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2 - DOI - PMC - PubMed

[2] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2 - DOI - PMC - PubMed

[3] Hammond J, Leister-Tebbe H, Gardner A, et al. ; EPIC-HR Investigators . Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542 - DOI - PMC - PubMed

[4] Hammond J, Leister-Tebbe H, Gardner A, et al. ; EPIC-HR Investigators . Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408. doi:10.1056/NEJMoa2118542 - DOI - PMC - PubMed

[5] Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554-564. doi:10.1001/jamainternmed.2023.0743 - DOI - PMC - PubMed

[6] Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183(6):554-564. doi:10.1001/jamainternmed.2023.0743 - DOI - PMC - PubMed

[7] Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381:e074572. doi:10.1136/bmj-2022-074572 - DOI - PMC - PubMed

[8] Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. BMJ. 2023;381:e074572. doi:10.1136/bmj-2022-074572 - DOI - PMC - PubMed

[9] Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US. PLoS Med. 2023;20(4):e1004194. doi:10.1371/journal.pmed.1004194 - DOI - PMC - PubMed

[10] Fung KW, Baye F, Baik SH, Zheng Z, McDonald CJ. Prevalence and characteristics of long COVID in elderly patients: An observational cohort study of over 2 million adults in the US. PLoS Med. 2023;20(4):e1004194. doi:10.1371/journal.pmed.1004194 - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients

Affiliations

Nirmatrelvir and Molnupiravir and Post-COVID-19 Condition in Older Patients

Authors

Affiliations

Plain language summary

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Plain language summary

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical